5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study

Psychopharmacology (Berl). 2003 Apr;167(1):72-8. doi: 10.1007/s00213-002-1379-5. Epub 2003 Mar 11.

Abstract

Objective: The aim of the study was to investigate differences in 5-HT(2A) receptor binding between healthy volunteers and patients with major depressive disorder (MDD), either never treated before with antidepressants (drug-naive: DN) or responding to paroxetine treatment (drug-treated: DT).

Methods: Nineteen DN patients with MDD and 15 euthymic DT (paroxetine 4 weeks) patients were compared with a group of 20 healthy controls (C) with positron emission tomography (PET) using [(18)F]fluoroethylspiperone ([(18)F]FESP), a 5-HT(2A) and D(2) receptor antagonist. A "binding index" (BI) of [(18)F]FESP to cortical and basal ganglia regions was calculated as the ratio of the activity in these regions to that of cerebellum. Differences in BI between groups, i.e. C versus DN or DT, were assessed by ANOVA, with or without age as covariate (ANCOVA).

Results: A significant reduction in BI ( P=0.003 ANOVA, P=0.001 ANCOVA) was found in DN patients in the frontal, occipital, temporal and cingulate cortices, but not in the striatum. No significant differences emerged between C and DT patients.

Conclusions: The reduction of [(18)F]FESP BI in cortical areas of DN depressed, but not of euthymic DT patients suggests an association between the occurrence of depressive symptoms and impairment of cortical 5-HT(2A) receptors. [(18)F]FESP cortical BI may represent a state marker of depression.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antidepressive Agents, Second-Generation / metabolism
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Case-Control Studies
  • Depressive Disorder, Major / diagnostic imaging
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Major / metabolism*
  • Dopamine Antagonists / metabolism
  • Female
  • Fluorine Radioisotopes
  • Humans
  • Ligands
  • Male
  • Middle Aged
  • Paroxetine / metabolism
  • Paroxetine / therapeutic use*
  • Receptor, Serotonin, 5-HT2A
  • Receptors, Dopamine D2 / drug effects
  • Receptors, Serotonin / drug effects
  • Receptors, Serotonin / metabolism*
  • Selective Serotonin Reuptake Inhibitors / metabolism
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Spiperone / analogs & derivatives*
  • Spiperone / metabolism
  • Tomography, Emission-Computed

Substances

  • Antidepressive Agents, Second-Generation
  • Dopamine Antagonists
  • Fluorine Radioisotopes
  • Ligands
  • Receptor, Serotonin, 5-HT2A
  • Receptors, Dopamine D2
  • Receptors, Serotonin
  • Serotonin Uptake Inhibitors
  • 3-N-(2-fluoroethyl)spiperone
  • Paroxetine
  • Spiperone